Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. [electronic resource]
Producer: 20030312Description: 960-5 p. digitalISSN:- 1524-4539
- Angiotensin-Converting Enzyme Inhibitors -- economics
- Canada
- Cost-Benefit Analysis
- Drug Costs -- statistics & numerical data
- Health Care Costs -- statistics & numerical data
- Heart Diseases -- economics
- Hospitalization
- Humans
- Multicenter Studies as Topic
- Myocardial Infarction -- prevention & control
- Placebos -- economics
- Ramipril -- economics
- Randomized Controlled Trials as Topic
- Risk
- Sensitivity and Specificity
- Stroke -- prevention & control
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.